Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Granisetron (TRG) for CINV
NCT00787566Phase 2Completed
- Sponsor
- Shin Nippon Biomedical Laboratories
- Start
- Oct 2008
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Granisetron Hydrochloride Nasal Spray in chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by Shin Nippon Biomedical Laboratories. Primary endpoint: Percentage of Patients With Complete Control at 24 hours. Started Oct 2008; status: completed.
02
Drugs
Granisetron Hydrochloride Nasal Spray
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00787566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00787566.